Multifaceted roles of PGE2 in inflammation and cancer

Dong M, Guda K, Nambiar PR, Rezaie A, Belinsky GS et al (2003) Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 24(2):307–315

Dong M, Johnson M, Rezaie A, Ilsley JN, Nakanishi M, et al. (2005) Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis. Clin Cancer Res 11(6):2265–71

Ilsley JN, Nakanishi M, Flynn C, Belinsky GS, De Guise S et al (2005) Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res 65(7):2636–2643

Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55(1):115–122

Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294(5548):1871–1875

Smith WL (1989) The eicosanoids and their biochemical mechanisms of action. Biochem J 259(2):315–324

Wang D, Mann JR, DuBois RN (2005) The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128(5):1445–1461

Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 96(13):7220–7225

Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y et al (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275(42):32783–32792

Tai HH, Cho H, Tong M, Ding Y (2006) NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr Pharm Des 12(8):955–962

Yan M, Rerko RM, Platzer P, Dawson D, Willis J et al (2004) 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 101(50):17468–17473

Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH et al (2005) 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280(5):3217–3223

Ding Y, Tong M, Liu S, Moscow JA, Tai HH (2005) NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26(1):65–72

Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J et al (2009) 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A 106(23):9409–9413

Myung SJ, Rerko RM, Yan M, Platzer P, Guda K et al (2006) 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 103(32):12098–12102

Backlund MG, Mann JR, Holla VR, Shi Q, Daikoku T et al (2008) Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res 68(22):9331–9337

Coleman RA, Smith WL, Narumiya S (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46(2):205–229

Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. J Biol Chem 282(16):11613–11617

Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41:661–690

Samuelsson B, Morgenstern R, Jakobsson PJ (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59(3):207–224

Kalinski P (2012) Regulation of immune responses by prostaglandin e2. J Immunol 188(1):21–28

Sakata D, Yao C, Narumiya S (2010) Prostaglandin E2, an immunoactivator. J Pharmacol Sci 112(1):1–5

Wallace JL (2001) Prostaglandin biology in inflammatory bowel disease. Gastroenterol Clin N Am 30(4):971–980

Uematsu S, Matsumoto M, Takeda K, Akira S (2002) Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J Immunol 168(11):5811–5816

Hara S, Kamei D, Sasaki Y, Tanemoto A, Nakatani Y et al (2010) Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models. Biochimie 92(6):651–659

Kojima F, Kapoor M, Yang L, Fleishaker EL, Ward MR et al (2008) Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice. J Immunol 180(12):8361–8368

Wang M, Song WL, Cheng Y, Fitzgerald GA (2008) Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease. J Intern Med 263(5):500–505

Iwakura Y, Ishigame H, Saijo S, Nakae S (2011) Functional specialization of interleukin-17 family members. Immunity 34(2):149–162

Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM et al (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8(9):950–957

Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ et al (2009) Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 206(3):535–548

Sheibanie AF, Khayrullina T, Safadi FF, Ganea D (2007) Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum 56(8):2608–2619

Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M et al (2007) The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23– > IL-17 axis. J Immunol 178(12):8138–8147

Fukunaga K, Kohli P, Bonnans C, Fredenburgh LE, Levy BD (2005) Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol 174(8):5033–5039

Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ et al (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5(6):698–701

Wallace JL (2006) COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. Sci World J 6:577–588

Yin H, Cheng L, Langenbach R, Ju C (2007) Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology 45(1):159–169

Scher JU, Pillinger MH (2009) The anti-inflammatory effects of prostaglandins. J Investig Med 57(6):703–708

Joshi PC, Zhou X, Cuchens M, Jones Q (2001) Prostaglandin E2 suppressed IL-15-mediated human NK cell function through down-regulation of common gamma-chain. J Immunol 166(2):885–891

Linnemeyer PA, Pollack SB (1993) Prostaglandin E2-induced changes in the phenotype, morphology, and lytic activity of IL-2-activated natural killer cells. J Immunol 150(9):3747–3754

Martinet L, Jean C, Dietrich G, Fournie JJ, Poupot R (2010) PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem Pharmacol 80(6):838–845

Yakar I, Melamed R, Shakhar G, Shakhar K, Rosenne E et al (2003) Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann Surg Oncol 10(4):469–479

Muthuswamy R, Mueller-Berghaus J, Haberkorn U, Reinhart TA, Schadendorf D et al (2010) PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood 116(9):1454–1459

Betz M, Fox BS (1991) Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 146(1):108–113

Snijdewint FG, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML (1993) Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 150(12):5321–5329

Allen JE, Wynn TA (2011) Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. PLoS Pathog 7(5):e1002003

Ae T, Ohno T, Hattori Y, Suzuki T, Hosono K et al (2010) Role of microsomal prostaglandin E synthase-1 in the facilitation of angiogenesis and the healing of gastric ulcers. Am J Physiol Gastrointest Liver Physiol 299(5):G1139–G1146

Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T et al (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109(7):883–893

Nakanishi M, Menoret A, Tanaka T, Miyamoto S, Montrose DC et al (2011) Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res (Phila) 4(8):1198–1208

Gurtner GC, Werner S, Barrandon Y, Longaker MT (2008) Wound repair and regeneration. Nature 453(7193):314–321

Montrose DC, Kadaveru K, Ilsley JN, Root SH, Rajan TV et al (2010) cPLA2 is protective against COX inhibitor-induced intestinal damage. Toxicol Sci 117(1):122–132

Iizuka M, Konno S (2011) Wound healing of intestinal epithelial cells. World J Gastroenterol: WJG 17(17):2161–2171

Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310(5753):1504–1510

Buchanan FG, Wang D, Bargiacchi F, DuBois RN (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278(37):35451–35457

Nakanishi M, Sato T, Li Y, Nelson AJ, Farid M et al (2012) Prostaglandin E2 stimulates the production of vascular endothelial growth factor through the E-prostanoid-2 receptor in cultured human lung fibroblasts. Am J Respir Cell Mol Biol 46(2):217–223

Guo X, Oshima H, Kitmura T, Taketo MM, Oshima M (2008) Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J Biol Chem 283(28):19864–19871

Zhang Y, Daaka Y (2011) PGE2 promotes angiogenesis through EP4 and PKA Cgamma pathway. Blood 118(19):5355–5364

Zhu Z, Fu C, Li X, Song Y, Li C et al (2011) Prostaglandin E2 promotes endothelial differentiation from bone marrow-derived cells through AMPK activation. PLoS One 6(8):e23554

Rao R, Redha R, Macias-Perez I, Su Y, Hao C et al (2007) Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 282(23):16959–16968

Sipos F, Valcz G, Molnar B (2012) Physiological and pathological role of local and immigrating colonic stem cells. World J Gastroenterol: WJG 18(4):295–301

Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ et al (2003) Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 29(5):537–544

Walker NM, Badri LN, Wadhwa A, Wettlaufer S, Peters-Golden M et al (2012) Prostaglandin E2 as an inhibitory modulator of fibrogenesis in human lung allografts. Am J Respir Crit Care Med 185(1):77–84

McCann MR, Monemdjou R, Ghassemi-Kakroodi P, Fahmi H, Perez G et al (2011) mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Res Ther 13(1):R6

Iwanaga K, Okada M, Murata T, Hori M, Ozaki H (2012) Prostaglandin E2 promotes wound-induced migration of intestinal subepithelial myofibroblasts via EP2, EP3, and EP4 prostanoid receptor activation. J Pharmacol Exp Ther 340(3):604–611

Harding P, LaPointe MC (2011) Prostaglandin E2 increases cardiac fibroblast proliferation and increases cyclin D expression via EP1 receptor. Prostaglandins Leukot Essent Fat Acids 84(5–6):147–152

Ayabe S, Murata T, Maruyama T, Hori M, Ozaki H (2009) Prostaglandin E2 induces contraction of liver myofibroblasts by activating EP3 and FP prostanoid receptors. Br J Pharmacol 156(5):835–845

Fischer SM, Hawk ET, Lubet RA (2011) Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res 4(11):1728–1735

Waddell WR, Ganser GF, Cerise EJ, Loughry RW (1989) Sulindac for polyposis of the colon. Am J Surg 157(1):175–179

Waddell WR, Loughry RW (1983) Sulindac for polyposis of the colon. J Surg Oncol 24(1):83–87

Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD et al (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83(5):355–358

Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325(23):1593–1596

Kawamori T, Uchiya N, Sugimura T, Wakabayashi K (2003) Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24(5):985–990

Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN (2005) Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 65(5):1822–1829

Wilson JW, Potten CS (2000) The effect of exogenous prostaglandin administration on tumor size and yield in Min/+ mice. Cancer Res 60(16):4645–4653

Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS et al (2008) Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 68(9):3251–3259

Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L et al (2001) Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121(6):1339–1347

Guda K, Upender MB, Belinsky G, Flynn C, Nakanishi M et al (2004) Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability. Oncogene 23(21):3813–3821

Nambiar PR, Nakanishi M, Gupta R, Cheung E, Firouzi A et al (2004) Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer. Cancer Res 64(18):6394–6401

Papanikolaou A, Wang QS, Papanikolaou D, Whiteley HE, Rosenberg DW (2000) Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 21(8):1567–1572

Chen EP, Smyth EM (2011) COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins Other Lipid Mediat 96(1–4):14–20

Markosyan N, Chen EP, Ndong VN, Yao Y, Sterner CJ et al (2011) Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis 32(10):1441–1449

Oshima H, Oshima M, Inaba K, Taketo MM (2004) Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J 23(7):1669–1678

Itadani H, Oshima H, Oshima M, Kotani H (2009) Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer. BMC Genomics 10:615

Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo MM et al (2006) Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology 131(4):1086–1095

Oshima H, Oguma K, Du YC, Oshima M (2009) Prostaglandin E2, Wnt, and BMP in gastric tumor mouse models. Cancer Sci 100(10):1779–1785

Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M et al (2002) Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 62(1):28–32

Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA et al (2006) Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 66(6):3106–3113

Doherty GA, Byrne SM, Molloy ES, Malhotra V, Austin SC et al (2009) Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer 9:207

Chandramouli A, Onyeagucha BC, Mercado-Pimentel ME, Stankova L, Shahin NA et al (2012) MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther 13(3):175–183

Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S et al (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59(20):5093–5096

Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T et al (2004) Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 53(8):1151–1158

Xia D, Wang D, Kim SH, Katoh H, DuBois RN (2012) Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med 18(2):224–226

Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F et al (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7(9):1048–1051

Jimenez P, Piazuelo E, Cebrian C, Ortego J, Strunk M et al (2010) Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma. Aliment Pharmacol Ther 31(3):440–451

Jin J, Chang Y, Wei W, He YF, Hu SS et al (2012) Prostanoid EP1 receptor as the target of (−)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro. Acta Pharmacol Sin 33(5):701–709

Amano H, Ito Y, Suzuki T, Kato S, Matsui Y et al (2009) Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis. Cancer Sci 100(12):2318–2324

Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392–401

Holt DM, Ma X, Kundu N, Collin PD, Fulton AM (2012) Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 35(2):179–188

Liu L, Ge D, Ma L, Mei J, Liu S et al (2012) Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol 7(7):1091–1100

Betts GJ, Clarke SL, Richards HE, Godkin AJ, Gallimore AM (2006) Regulating the immune response to tumours. Adv Drug Deliv Rev 58(8):948–961

Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182(8):4499–4506

Izcue A, Coombes JL, Powrie F (2009) Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 27:313–338

Fehervari Z, Sakaguchi S (2004) CD4+ Tregs and immune control. J Clin Investig 114(9):1209–1217

Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N et al (2005) Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175(3):1483–1490

Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B et al (2005) Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 65(12):5211–5220

Yuan XL, Chen L, Li MX, Dong P, Xue J et al (2010) Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin Immunol 134(3):277–288

Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM et al (2008) Enhanced functionality of CD4 + CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res 14(4):1032–1040

Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY et al (2009) The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother 32(1):22–28

Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Jackson EK et al (2010) Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 285(36):27571–27580

Soontrapa K, Honda T, Sakata D, Yao C, Hirata T et al (2011) Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc Natl Acad Sci U S A 108(16):6668–6673

Pinchuk IV, Beswick EJ, Saada JI, Boya G, Schmitt D et al (2011) Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells. Gastroenterology 140(7):2019–2030

Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174

Lu T, Gabrilovich DI. (2012) Molecular Pathways : Tumor Infiltrating Myeloid Cells and Reactive Oxygen Species in Regulation of Tumor Microenvironment. Clin Cancer Res Off J Am Assoc Cancer Res 18(18):1–6

Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253–268

Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P (2011) Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118(20):5498–5505

Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P (2011) PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71(24):7463–7470

Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67(9):4507–4513

Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J et al (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69(4):1553–1560

Li Y, Yin S, Nie D, Xie S, Ma L et al (2011) MK886 inhibits the proliferation of HL-60 leukemia cells by suppressing the expression of mPGES-1 and reducing prostaglandin E2 synthesis. Int J Hematol 94(5):472–478

Deckmann K, Rorsch F, Geisslinger G, Grosch S (2012) Dimethylcelecoxib induces an inhibitory complex consisting of HDAC1/NF-kappaB(p65)RelA leading to transcriptional downregulation of mPGES-1 and EGR1. Cell Signal 24(2):460–467

Deckmann K, Rorsch F, Steri R, Schubert-Zsilavecz M, Geisslinger G et al (2010) Dimethylcelecoxib inhibits mPGES-1 promoter activity by influencing EGR1 and NF-kappaB. Biochem Pharmacol 80(9):1365–1372

Koeberle A, Siemoneit U, Buhring U, Northoff H, Laufer S et al (2008) Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 326(3):975–982

Cote B, Boulet L, Brideau C, Claveau D, Ethier D et al (2007) Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 17(24):6816–6820

Giroux A, Boulet L, Brideau C, Chau A, Claveau D et al (2009) Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 19(20):5837–5841

Chini MG, De Simone R, Bruno I, Riccio R, Dehm F et al (2012) Design and synthesis of a second series of triazole-based compounds as potent dual mPGES-1 and 5-lipoxygenase inhibitors. Eur J Med Chem 54:311–323

Beales IL, Ogunwobi OO (2010) Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production. Int J Cancer J Int Cancer 126(9):2247–2255

Chang HH, Meuillet EJ (2011) Identification and development of mPGES-1 inhibitors: where we are at? Future Med Chem 3(15):1909–1934

Moon Y, Glasgow WC, Eling TE (2005) Curcumin suppresses interleukin 1beta-mediated microsomal prostaglandin E synthase 1 by altering early growth response gene 1 and other signaling pathways. J Pharmacol Exp Ther 315(2):788–795

Koeberle A, Northoff H, Werz O (2009) Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. Mol Cancer Ther 8(8):2348–2355

Koeberle A, Bauer J, Verhoff M, Hoffmann M, Northoff H et al (2009) Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1. Biochem Biophys Res Commun 388(2):350–354

Koeberle A, Pollastro F, Northoff H, Werz O (2009) Myrtucommulone, a natural acylphloroglucinol, inhibits microsomal prostaglandin E(2) synthase-1. Br J Pharmacol 156(6):952–961

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539–545

Aggarwal BB, Gehlot P (2009) Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 9(4):351–369

Waldner MJ, Neurath MF (2009) Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 31(2):249–256

Lewis JD, Deren JJ, Lichtenstein GR (1999) Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin N Am 28(2):459–477, x

Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD et al (2012) Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 143(2):382–389

Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140(6):1807–1816

Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315(26):1650–1659

Schafer M, Werner S (2008) Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 9(8):628–638

Hong KH, Bonventre JC, O'Leary E, Bonventre JV, Lander ES (2001) Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc Natl Acad Sci U S A 98(7):3935–3939

Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW et al (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60(17):4705–4708

Ishikawa TO, Herschman HR (2010) Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 31(4):729–736

Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803–809

Elander N, Ungerback J, Olsson H, Uematsu S, Akira S et al (2008) Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice. Biochem Biophys Res Commun 372(1):249–253

Sasaki Y, Kamei D, Ishikawa Y, Ishii T, Uematsu S et al (2012) Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. Oncogene 31(24):2943–2952

Okuyama T, Ishihara S, Sato H, Rumi MA, Kawashima K et al (2002) Activation of prostaglandin E2-receptor EP2 and EP4 pathways induces growth inhibition in human gastric carcinoma cell lines. J Lab Clin Med 140(2):92–102

Liu CH, Chang SH, Narko K, Trifan OC, Wu MT et al (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21):18563–18569

Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ et al (2005) HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 65(21):10113–10119

Sung YM, He G, Fischer SM (2005) Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 65(20):9304–9311